French drugmaker Sanofi and Britain’s GlaxoSmithKline started a clinical trial of their protein-based Covid-19 vaccine candidate, with the companies aiming to reach the final testing stage by December.

French drugmaker Sanofi SA expects to get approval for the potential COVID-19 vaccine in development with Britain’s GlaxoSmithKline Plc by the first half of 2021, faster than previously anticipated.